347 related articles for article (PubMed ID: 26238110)
1. Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement System.
Kohler JC; Mitsakakis N; Saadat F; Byng D; Martinez MG
Global Health; 2015 Aug; 11():34. PubMed ID: 26238110
[TBL] [Abstract][Full Text] [Related]
2. Enhancing medicine price transparency through price information mechanisms.
Hinsch M; Kaddar M; Schmitt S
Global Health; 2014 May; 10():34. PubMed ID: 24885767
[TBL] [Abstract][Full Text] [Related]
3. Retail prices of essential drugs in Brazil: an international comparison.
Nóbrega Ode T; Marques AR; de Araújo AC; Karnikowski MG; Naves Jde O; Silver LD
Rev Panam Salud Publica; 2007 Aug; 22(2):118-23. PubMed ID: 17976278
[TBL] [Abstract][Full Text] [Related]
4. Analysis of State-Level Drug Pricing Transparency Laws in the United States.
Ryan MS; Sood N
JAMA Netw Open; 2019 Sep; 2(9):e1912104. PubMed ID: 31553467
[TBL] [Abstract][Full Text] [Related]
5. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.
Moodley R; Suleman F
BMC Health Serv Res; 2019 Aug; 19(1):576. PubMed ID: 31419977
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004-2011.
Luo J; Oliveira MA; Ramos MB; Maia A; Osorio-de-Castro CG
BMC Public Health; 2014 Apr; 14():367. PubMed ID: 24735589
[TBL] [Abstract][Full Text] [Related]
8. Value-based differential pricing: efficient prices for drugs in a global context.
Danzon P; Towse A; Mestre-Ferrandiz J
Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
[TBL] [Abstract][Full Text] [Related]
9. Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.
Wilson L; Turkistani F; Tran DM; Huang W; Lin TK
Appl Health Econ Health Policy; 2019 Apr; 17(2):231-242. PubMed ID: 30484140
[TBL] [Abstract][Full Text] [Related]
10. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
Stargardt T; Schreyögg J
Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study.
Dave CV; Pawar A; Fox ER; Brill G; Kesselheim AS
Value Health; 2018 Nov; 21(11):1286-1290. PubMed ID: 30442275
[TBL] [Abstract][Full Text] [Related]
12. Discounting of medicines in Australian community pharmacies.
Thai LP; Vitry AI; Moss JR
Aust Health Rev; 2014 Nov; 38(5):517-22. PubMed ID: 25099433
[TBL] [Abstract][Full Text] [Related]
13. Pricing of HPV tests in Italian tender-based settings.
Inturrisi F; Berkhof J
J Med Econ; 2022; 25(1):762-768. PubMed ID: 35616231
[TBL] [Abstract][Full Text] [Related]
14. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment.
Mahlich J; Kamae I; Sruamsiri R
Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):339-348. PubMed ID: 29039214
[TBL] [Abstract][Full Text] [Related]
16. Assistive technology pricing in Australia: is it efficient and equitable?
Summers MP; Verikios G
Aust Health Rev; 2018 Feb; 42(1):100-110. PubMed ID: 28160784
[TBL] [Abstract][Full Text] [Related]
17. International trade and determinants of price differentials of insulin medicine.
Helble M; Aizawa T
Health Policy Plan; 2017 Feb; 32(1):1-10. PubMed ID: 27346189
[TBL] [Abstract][Full Text] [Related]
18. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
Vacca C; Acosta A; Rodriguez I
Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
[TBL] [Abstract][Full Text] [Related]
19. Determinants of branded prescription medicine prices in OECD countries.
Kanavos PG; Vandoros S
Health Econ Policy Law; 2011 Jul; 6(3):337-67. PubMed ID: 21676345
[TBL] [Abstract][Full Text] [Related]
20. International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
Rand LZ; Kesselheim AS
Value Health; 2021 Apr; 24(4):473-476. PubMed ID: 33840424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
